Sangamo slides on delayed readout for hemophilia A gene therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) said on its 3Q18 earnings call late Thursday that it will not submit a late-breaking abstract to present Phase I/II data for its hemophilia A gene therapy at next month's American Society of Hematology (ASH) meeting.

Sangamo lost $2.47 (18%) to $11.15 on Friday, representing a loss of over $250 million in market cap...